Noninvasive Medical Technologies

January 11, 2008

G&M Compliance
154 Cypress
Orange, CA 92866

**CC:**
North West EMC, Inc.
22975 NW Evergreen Parkway, #400
Hillsboro, OR 97124

Compliance Certification Services
561F Monterey Road,
Morgan Hills, CA 95037

**NMT FRN: 0017312117**
**Grantee Code: VXZ**

**FCC ID: VXZNMT-NCIQ2**
**FCC EMC: FCC 15.249**

To Whom It May Concern:

Noninvasive Medical Technologies requests an original limited modular approval for a 915 MHz RFII radio in the NcIQ. The NcIQ is intended for sale within the United States of America, Canada, and Europe. This new innovation measures and reports critical hemodynamic data of casualties or patients as well as their location which is reported to an electronic platform such as a laptop or PDA, used by the medic or first responder.

The 915 MHz radio can be co-located with a 2.4 GHz radio. Within the device are two intentional radiators; 1. a new innovation referred to as the Transducer Antenna Probe (TAP) (915mHz) that is connected to the Radio Frequency Impedance Interrogator (RFII) circuit, and 2. the Freescale radio (2.4GHz) and antenna. The TAP and RFII circuit measure reflected impedance from the anatomical structures within the thorax. The bottom side of the device is placed over the area of the heart on the chest and is intended for use on the outside of the clothes or directly on the chest. This statement indicates that the correct utilization of the device is for measurement within 20cm of the chest.

The TAP sends the 915 MHz signal into the chest and receives a return signal which is analyzed by the RFII circuitry and sent to an atmel. The atmel analyzes the signal, measuring heart rate, respirations, cardiac output and the change in trend of these three

medical signs reported as Life Score. The data reported to the electronic platform used by the medic or clinician is sent from the Freescale radio at 2.4GHz.

The intended clinical environments are first responders, fire fighters, medics, hazmat teams, and emergency crews during disaster response. Once FCC approval and all product safety requirements have been tested and met, NMT will submit the NcIQ for FDA 510K approval.

Thank you,

*Ann McCaughan*

Ann McCaughan
Chief Operating Officer/Chief Technologies Officer
Noninvasive Medical Technologies, Inc.
6412 S. Arville
Las Vegas, NV 89118
888-466-8552
amccaughan@nmtinc.org